{"id":363,"date":"2020-07-09T16:51:59","date_gmt":"2020-07-09T16:51:59","guid":{"rendered":"http:\/\/sites.rutgers.edu\/jun-wang-lab\/?page_id=363"},"modified":"2026-03-23T19:32:16","modified_gmt":"2026-03-23T19:32:16","slug":"publications","status":"publish","type":"page","link":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

For complete list of publications:
\nGoogle Scholar<\/a>
\nORCID<\/a>
\nPublons<\/a>
\nPubMed<\/a><\/p>\n

Publications (# equal contribution * Corresponding author)<\/p>\n

Year 2026<\/strong><\/span><\/p>\n

138. Li K, Ni J, Fan G, Wang J* Rational design of capsid protein VP1 degraders to overcome pleconaril resistance in inhibiting enterovirus D68.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0J Am Chem Soc Au 2026<\/strong><\/em><\/a>, ASAP<\/p>\n

\"\"<\/p>\n

137. Li K, Rudy MJ, Klose T, Tan H, Wu X, Demssie HA, Anderson JS, Jadhav P, Zhang QY, Clarke P, Kuhn RJ,* Tyler KL,* Wang J.* Rational design and in vivo validation of capsid inhibitors for enterovirus D68. Nat Commun.<\/strong> <\/em><\/a>2026 Feb 10. doi: 10.1038\/s41467-026-69351-x. Epub ahead of print. PMID: 41667472.<\/p>\n

\"\"<\/p>\n

136. Cai Z,# Kohaal N,# Georgiou K, Liang X, Chi X, Tan H, Tan B, Li K, Fan G, Lambrinidis G, Kolocouris A, Deng X, Chen Y,* Wang, J* Structure-based design of covalent SARS-CoV-2 main protease inhibitors targeting the nirmatrelvir-resistant E166 mutants. J Am Chem Soc Au<\/strong><\/em><\/a> 2026, 6, 233-244.<\/p>\n

\"\"<\/p>\n

135. Tan H, Chi X, Deng X,* Wang, J* Characterization of the cross resistance of SARS-CoV-2 main protease inhibitors, ibuzatrelvir, ensitrelvir, and nirmatrelvir. ACS Pharmacol Transl Sci<\/strong> <\/em><\/a>2026, 9, 404-413.<\/p>\n

\"\"<\/p>\n

Year 2025<\/strong><\/span><\/p>\n

134. Li K,# Rudy MJ,# Hu Y,# Tan H,# Lambrinidis G, Wu X, Georgiou K, Tan B, Frost J, Wilson C, Clarke P, Kolocouris A, Zhang QY, Tyler KL,* Wang J.* A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis. Nat Commun.<\/strong><\/em><\/a> 2025, 16, 5987.<\/p>\n

\"\"<\/p>\n

133. Tan H, Li K, Wang J.* Serial viral passage and reverse genetics protocol for identifying the antiviral drug targets of EV-D68 antivirals. STAR Protoc.<\/strong><\/em><\/a> 2025, 6, 104053.<\/p>\n

\"\"<\/p>\n

132. Yang W, Wang L, Shi L, Zhang J, Liu H, Wang J, Ma W.* Bat Influenza M2 Shows Functions Similar to Those of Classical Influenza A Viruses. Pathogens<\/strong><\/em><\/a>. 2025, 14, 599.<\/p>\n

\"\"<\/p>\n

131. Li K, Demssie HA, Wang J.* Design of a Fluorescence Polarization Probe for Enterovirus 2C Proteins. J. Med. Chem.<\/strong><\/em><\/a> 2025, 68, 14041-14053.<\/p>\n

\"\"<\/p>\n

130. Tan H,# Zhang Q,# Georgiou K, Zhang S, Li K, Lambrinidis G, Kolocouris A, Deng X,* Wang, J*.<\/i>\u00a0Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease.\u00a0Nat. Commun.<\/i><\/strong><\/a> 2025, 16, 4548.<\/p>\n

\"\"<\/p>\n

129. Li K, Jadhav P, Wen Y, Tan H, Wang, J.* Development of a fluorescence polarization assay for the SARS-CoV-2 papain-like protease. ACS Pharmacol. Transl. Sci.<\/strong><\/em><\/a> 2025, 8, 774-784.<\/p>\n

\"\"<\/p>\n

128. Jadhav P,# Liang X,# Ansari A,# Tan B,# Tan H, Li K, Chi X, Ford A, Ruiz FX,* Arnold E,* Deng X,* Wang J.* Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates. Nat. Commun.<\/strong><\/em> <\/a>2025, 16, 1604.<\/p>\n

\"\"<\/p>\n

127. Lewandowski EM,# Zhang X,# Tan H,# Jaskolka-Brown A, Kohaal N, Frazier A, Madsen JJ, Jacobs LMC, Wang J,* Chen Y.* Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance. Nat. Commun.<\/i><\/a>\u00a0<\/strong>2025, 16, 1266.<\/p>\n

\"Fig.<\/p>\n

 <\/p>\n

Year 2024<\/strong><\/span><\/p>\n

126. Tan H, Pollard B, Li K, Wang J.* Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein. ACS Infect. Dis.<\/strong> <\/em><\/a>2024, 10, 4327-4336.<\/p>\n

\"\"<\/p>\n

125. Tan B,# Liang X,# Ansari A,# Jadhav P, Tan H, Li K, Ruiz FX,* Arnold E,* Deng X,* Wang J.* Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors. J. Med. Chem.<\/strong> <\/em><\/a>2024, 67, 20399-20420.<\/p>\n

\"\"<\/p>\n

124. Yang P, Gao S, Shen J, Liu T, Lu K, Han X, Wang J, Ni HM, Ding WX, Li H, Pan JA, Peng K, Zong WX. TRIM21-mediated ubiquitination of SQSTM1\/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity. Autophagy<\/em><\/strong><\/a>. 2025, 21, 178-190.<\/p>\n

\"\"<\/p>\n

123. Atomwise AIMS Program. AI is a viable alternative to high throughput screening: a 318-target study. Sci. Rep.<\/strong><\/em><\/a> 2024, 14, 7526.<\/p>\n

122. Pankratova Y, McKay MJ, Ma C, Tan H, Wang J, Hong M.* Structure and dynamics of the proton-selective histidine and the gating tryptophan in an inward rectifying hybrid influenza B and A virus M2 proton channel. Phys. Chem. Chem. Phys.<\/strong><\/em><\/a> 2024, 26, 20629-20644.<\/p>\n

\"Graphical<\/p>\n

121. Tan B,# Zhang X,# Ansari A,# Jadhav P,# Tan H, Li K, Chopra A, Ford A, Chi X, Ruiz FX,* Arnold E,* Deng X,* Wang J.* Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science<\/strong><\/em><\/a>. 2024, 383, 1434-1440.<\/p>\n

\"\"<\/p>\n

Year 2023<\/strong><\/span><\/p>\n

120. Jadhav P,# Huang B,# Osipiuk J,# Zhang X, Tan H, Tesar C, Endres M, Jedrzejczak R, Tan B, Deng X, Joachimiak A,* Cai J,* Wang J.* Structure-based design of SARS-CoV-2 papain-like protease inhibitors. Eur. J. Med. Chem.<\/strong><\/em><\/a> 2023, 264, 116011.<\/p>\n

\"\"<\/p>\n

119. Tan B, <\/span>Liu C,\u00a0<\/span>Li K,\u00a0<\/span>Jadhav P, <\/span>Lambrinidis G,\u00a0<\/span>Zhu L,\u00a0<\/span>Olson L,\u00a0<\/span>Tan H,\u00a0<\/span>Wen Y, <\/span>Kolocouris A,\u00a0<\/span>Liu W, <\/span>Wang J<\/span>* <\/strong>Structure-Based Lead Optimization of Enterovirus D68 2A Protease Inhibitors. J. Med. Chem. <\/strong><\/em><\/a>2023, 66, 14544-14563.\u00a0<\/span><\/p>\n

\n
<\/div>\n<\/div>\n

\"\"<\/p>\n

 <\/p>\n

118. Ou J, Lewandowski EM, Hu Y, Lipinski AA, Aljasser A, Colon-Ascanio M, Morgan RT, Jacobs LMC, Zhang X, Bikowitz MJ, Langlais PR, Tan H, Wang J,* Chen Y,* Choy JS.* A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations. PLoS Pathog.<\/strong><\/em><\/a> 2023, 19, e1011592.<\/p>\n

\"\"<\/p>\n

117. Somberg NH, Medeiros-Silva J, Jo H, Wang J, DeGrado WF, Hong M.* Hexamethylene Amiloride Binds the SARS-CoV-2 Envelope Protein at the Protein-Lipid Interface. Protein Sci.<\/strong><\/em><\/a> 2023, 32, e4755.<\/p>\n

\"\"<\/p>\n

116. Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X,* Chen Y,* Wang J.* Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent. Sci.<\/strong><\/em><\/a> 2023, 9, 1658-1669.<\/p>\n

\"\"<\/p>\n

115. Tan B, Sacco M, Tan H, Li K, Joyce R, Zhang X, Chen Y, Wang J.* Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. Eur. J. Med. Chem.<\/strong><\/em><\/a> 2023, 259, 115667.<\/p>\n

\"\"<\/p>\n

114. Hoffman A, Stampolaki M, Tzitzoglaki C, Schmerer P, Ma C, D\u00f6ring K, Turcu A, Wang J, Vazquez S, Schmidtke M, Kolokouris A,* Stylianakis I, Movellan KT, Andreas L, Becker S. Adamantyl Amines Activity Study Against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple blocker Explored with MD simulations and Solid state NMR. ChemMedChem.<\/strong> <\/em><\/a>2023,18, e202300182.<\/p>\n

\"\"<\/p>\n

113. Tan H, Hu Y, Wang J.* FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro<\/sup>\u00a0and PLpro<\/sup>. STAR Protoc.<\/strong><\/em><\/a> 2023, 4, 102323.<\/p>\n

\"\"<\/p>\n

112. Frost J, Rudy MJ, Leser JS, Tan H, Hu Y, Wang J, Clarke P, Tyler KL.* Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis. J. Virol.<\/strong><\/em><\/a> 2023, 97, e0015623.\"\"<\/p>\n

111. Wang J,* Shahed-Ai-Mahmud M, Chen A, Li K, Tan H, Joyce R. An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses. J. Med. Chem.<\/em> <\/strong><\/a>(perspective) 2023, 66, 4468-4490.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

110. Wang L, Ma C, Sacco MD, Xue S, Mahmoud M, Calcul L, Chen Y,* Wang J,* Cai J.* Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained \u03b1, \u03b3-AA Peptide Scaffold. Chemistry<\/strong><\/em>.<\/a> 2023, 29, e202300476.<\/p>\n

\"\"<\/p>\n

109. Tan B, Joyce R, Tan H, Hu Y, Wang, J* SARS-CoV-2 main protease drug design, assay development, and drug resistance studies. Acc. Chem. Res.<\/strong> <\/em><\/a>2023, 56, 157-168.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Year 2022<\/strong><\/span><\/p>\n

108. Tzitzoglaki C, Hoffmann A, Turcu A, Schmerer P, Ma C, Laros G, Liolios C, Jose B, Wang J, Vazquez S, Schmidtke M,* Kolocouris A.* Amantaidne variant – Aryl conjugates that inhibit multiple M2 mutant – amantadine resistant influenza A viruses. Eur. J. Med. Chem. Rep.<\/strong><\/em><\/a> 2022, 6, 100083.<\/p>\n

\"\"<\/p>\n

107. Joyce R, Hu V, Wang J*. The history, mechanism, and perspective of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res.<\/strong><\/em><\/a> 2022, 31, 1637-1646. (special issue in honor of Prof. Edmond J. LaVoie)<\/p>\n

\"\"<\/p>\n

106. Potter C, Hu Y, Xiong Z, Wang J, McLeod E.* Point-of-care SARS-CoV-2 sensing using lens-free imaging and a deep learning-assisted quantitative agglutination assay. Lab Chip<\/strong><\/em>.<\/a> 2022, 22, 3744-3754.<\/p>\n

\"\"<\/p>\n

105. Sacco MD, Wang S, Adapa SR,\u00a0Zhang X,\u00a0Lewandowski EM,\u00a0Gongora MV, Keramisanou D, Atlas ZD, Townsend JA, Gatdula JR,\u00a0Morgan RT, Hammond LR, Marty MT, Wang J, Eswara PJ, Gelis I, Jiang RHY, Sun X,* Chen Y.* A unique class of Zn2+-binding serine-based PBPs underlies cephalosporin resistance and sporogenesis in Clostridioides difficile<\/em>. Nat. Commun.<\/strong><\/em><\/a> 2022, 13, 4370.<\/p>\n

104. Gomez K, Tang C, Tan B, Perez-Miller S, Ran D, Loya S, Calderon-Rivera A, Stratton H, Duran P, Masterson K, Gabrielsen A, Alsbiei O, Dorame A, Serafini M, Moutal A, Wang J,* Khanna R.* Stereospecific effects of benzimidazolonepiperidine compounds on T-type Ca2+ channels and pain. ACS Chem. Neurosci.<\/strong><\/em><\/a> 2022,13, 2035-2047.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

103. Tan H, Hu Y, Jadhav P, Tan B, Wang J.* Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem.<\/a>\u00a0<\/strong><\/em>(perspective) 2022, 65, 7561-7580.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

102. Zhou X, Zhu L, Bondy C, Wang J, Luo Q, Chen Y.* AG1478 elicits a novel anti-influenza function via an EGFR-independent, GBF1-dependent pathway. Int. J. Mol. Sci.<\/strong><\/em> <\/a>2022, 23, 5557.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

101. Tan H, Ma C, Wang J.*\u00a0 Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med. Chem. Res.<\/strong><\/em> <\/a>2022, 31, 1147-1153. (Special issue in honor of Prof. Laurence Hurley).<\/p>\n

\"\"<\/p>\n

 <\/p>\n

100. Wang J,* Li, H.* Editorial of Special Column on Antiviral Drug Discovery and Pharmacology. Acta Pharm. Sin. B<\/strong><\/em><\/a> 2022, 12, 1540-1541.<\/p>\n

 <\/p>\n

99. Ma C,# Hu Y,# Wang Y, Choza, J,<\/span>\u00a0<\/span>Wang J.* Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor. <\/span>ACS Infect. Dis.<\/strong><\/em><\/a> 2022, 8, 1022-1030. <\/span><\/p>\n

\"\"<\/a><\/p>\n

98. Sacco M, Hu Y, Gongora M, Meilleur F, Kemp M, Zhang X, Wang J,* Chen Y.* The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small molecule drug inhibition. Cell Res.<\/strong><\/em> <\/a>2022, 32, 498-500.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

97. Hu Y, Ma C, Wang J.* Cytopathic effect assay and plaque assay to evaluate in vitro activity of antiviral compounds against human coronaviruses 229E, OC43 and NL63. Bio-protocol<\/strong><\/em> <\/a>2022, 12, e4314.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

96. Hu Y, Jo H, DeGrado WF, Wang J.* Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell. J. Med. Virol.<\/em><\/strong><\/a> 2022, 94, 2188-2200.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

95. Ma C, Wang J.* Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors. ACS Pharmacol. Transl. Sci.<\/strong><\/em> <\/a>2022, 5, 102-109.<\/p>\n

\"\"<\/p>\n

Year 2021<\/strong><\/span><\/p>\n

94. Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, Choza J, Tan H, Jang J, Gongora MV, Zhang X, Zhang F, Xiang Y, Marty MT, Chen Y,* Wang J.* Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. J. Am. Chem. Soc.<\/strong><\/em><\/a> 2021, 143, 20697-20709.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

93. Townsend JA, Sanders HM, Rolland AD, Park CK, Horton NC, Prell JS, Wang J, Marty MT.* Influenza AM2 Channel Oligomerization Is Sensitive to Its Chemical Environment. Anal. Chem.<\/strong><\/em> <\/a>2021, 93, 16273-16281.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

92. Ma C, Tan H, Choza J, Wang Y, Wang J.* Validation and invalidation of SARS-CoV-2 main protease inhibitors using the FlipGFP and Protease-Glo luciferase assays. Acta Pharm. Sin. B<\/strong><\/em><\/a> 2022, 12, 1636-1651.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

91. Boras B, Jones RM,* Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O’ Brien MN, O’Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, Garc\u00eda-Sastre A, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun.<\/strong><\/em><\/a> 2021, 12, 6055.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

90. C\u00e1ceres CJ,\u00a0 Hu Y,\u00a0 C\u00e1rdenas-Garc\u00eda S,\u00a0 Tan H,\u00a0 Wu X, Carnaccini S,\u00a0 Gay LC, Geiger G, Ma C, Zhang QY,\u00a0 Rajao D, Perez DR,* Wang J.* Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerg. Microbes Infect.<\/strong><\/em><\/a> 2021, 10, 1832-1848.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

89. Wang J,* Hu Y, Zheng, M. Enterovirus 71 antivirals: past, present, and future.\u00a0 Acta Pharm. Sin. B.<\/strong><\/em><\/a> 2022, 12, 1542-1566.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

88. Thomaston JL, Samways ML, Konstantinidi A, Ma C, Hu Y, Bruce Macdonald HE, Wang J, Essex JW, DeGrado WF,* Kolocouris A.* Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity. Biochemistry<\/strong><\/em>.<\/a> 2021, 60, 2471-2482.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

87. Xia Z,# Sacco M,# Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y,* Wang J.* Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol. Transl. Sci.<\/strong><\/em><\/a> 2021, 4, 1408-1421.\"\"<\/p>\n

 <\/p>\n

86. Ma C,# Sacco MD,# Xia Z,# Lambrinidis G, Townsend JA, Hu Y, Meng X, Szeto T, Ba M, Zhang X, Gongora M, Zhang F, Marty MT, Xiang Y, Kolocouris A, Chen Y,* Wang J.* Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent. Sci.<\/strong><\/em><\/a> 2021, 7, 1245-1260.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

85. Hu Y,# Kitamura N,# Musharrafieh R, Wang J.* Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein. J. Med. Chem.<\/strong><\/em><\/a> 2021, 64, 8755-9774.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

84. Zhao H, Jiang S, Ye Z, Zhu H, Hu B, Meng P, Hu Y, Zhang H, Wang K,* Wang J,* Tian Y.* Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. Eur. J. Med. Chem.<\/strong><\/em><\/a> 2021, 221, 113567.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

83. C\u00e1ceres CJ, Cardenas-Garcia S, Carnaccini S, Seibert B, Rajao DS, Wang J,* Perez DR.* Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci. Rep.<\/strong><\/em><\/a> 2021, 11, 9609.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

82.\u00a0Kitamura N, Sacco MD, Ma C, Hu Y, Townsend JA, Meng X, Zhang F, Zhang X, Ba M, Szeto T, Kukuljac A, Marty MT, Schultz D, Cherry S, Xiang Y, Chen Y,* Wang J.* (2021) Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.\u00a0J. Med. Chem.<\/strong><\/em><\/a> 2022, 65, 2848-2865.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

81. Hu Y, Ma C, Szeto T, Hurst B, Tarbet B, Wang J.* Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronavirues.\u00a0 ACS Infect. Dis.<\/strong><\/em><\/a> 2021, 7, 586-597.\"\"<\/p>\n

 <\/p>\n

80. Hu Y, Meng X, Zhang F, Xiang Y, Wang J.* The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.\u00a0 Emerg. Microbes Infect.<\/strong><\/em><\/a> 2021,10, 317-330.<\/p>\n

\"\"\u200b<\/p>\n

79. Ma C, Wang J.* Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. U.S.A.<\/strong><\/em><\/a> 2021, 118, e2024420118. (Letter to the editor).<\/p>\n

\"\"<\/p>\n

Year 2020<\/span><\/strong><\/p>\n

78. Sacco M, Ma C, Lagarias P, Gao A, Townsend J, Meng X, Dube P, Zhang X, Hu Y, Kitamura N, Hurst B, Tarbet B, Marty M, Kolocouris A, Chen Y,* Wang J.* Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L. Sci. Adv.<\/strong> <\/em><\/a>2020, 6, eabe0751.<\/p>\n

\"\"<\/p>\n

77. Ma C, Hu Y, Townsend J, Lagarias P, Marty M, Kolocouris A, Wang J.* Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol. Transl. Sci.<\/strong><\/em> <\/a>2020, 3, 1265-1277.<\/p>\n

\"\"<\/p>\n

76. Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina N, Ma C, Papanastasiou I, Schreiner P, Vazques S, Schmidtke M, Wang J, Busath D, Kolocouris A.* Chemical probes for blocking of the influenza A M2 WT and S31N channels. ACS Chem. Biol.<\/strong><\/em><\/a> 2020, 15, 2331-2337.<\/p>\n

\"\"<\/p>\n

75. Ma C, Hu Y, Zhang J, Wang J.* Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect. Dis.<\/strong><\/em><\/a> 2020, 6, 2260-2270.<\/p>\n

\"\"<\/p>\n

74. Cai S, Tuohy P, Ma C, Kitamura N, Gomez K, Zhou Y, Ran D, Bellampalli S, Yu J, Luo S, Dorame A, Ngan P, Nancy Y, Molnar G, Streicher J, Patek M, Perez-Miller S, Moutal A, Wang J,* Khanna R.*\u00a0 A modulator of low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. Pain<\/strong><\/em> <\/a>2020, 161, 2551-2570.\"\"<\/p>\n

73. Musharrafieh R, Kitamura N, Hu Y, Wang J.* Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg. Chem.<\/strong><\/em><\/a> 2020, 101, 103981.<\/p>\n

\"\"<\/p>\n

72. Ma C, Sacco M, Hurst B, Townsend J, Hu Y, Szeto T, Zhang X, Tarbet B, Marty M, Chen Y,* Wang J.* Boceprevir, GC-376, and calpain inhibitors II and XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res.<\/strong><\/em><\/a> 2020, 30, 678-692.<\/p>\n

\"\"<\/p>\n

71. Hu Y, Musharrafieh R, Zheng M, Wang J.* Enterovirus D68 antivirals: past, present, and future.\u00a0 ACS Infect. Dis.<\/strong><\/em> <\/a>2020, 6, 1572-1586.<\/p>\n

\"\"<\/p>\n

70. Musharrafieh R, Lagarias P, Ma CL, Hau, R, Romano A, Lambrinidis G, Kolocouris A,* Wang J.* Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments. ACS Pharmacol. Trans. Sci.<\/strong> <\/em><\/a>2020, 3, 666-675.<\/p>\n

\"\"<\/p>\n

69. Jalily PH, Duncan MC, Fedida D, Wang J, Tietjen I.* Put a cork in it: plugging the M2 viral ion channel to sink influenza. Antiviral Res.<\/strong><\/em><\/a> 2020, 178, 104780.<\/p>\n

\"\"<\/p>\n

68. Thomaston JL, Konstantinidi A, Liu L, Lambrinidis G, Tan J, Caffrey M, Wang J, Degrado WF,* Kolocouris A.* X-ray crystal structures of the influenza M2 proton channel drug-resistant V27A mutant bound to a spiro-adamantyl amine inhibitor reveal the mechanism of amantadine resistance. Biochemistry.<\/strong><\/em> <\/a>2020, 59, 627-634. \"\"<\/p>\n

67. Zhang, J., Hu, Y.,\u00a0Wu, N., Wang, J.* Discovery of influenza polymerase PA-PB1 interaction inhibitors using an in vitro split-luciferase complementation-based assay.\u00a0ACS Chem. Biol.<\/strong> <\/em><\/a>2020, 15, 74-82.<\/p>\n

\"\"<\/p>\n

Year 2019<\/span><\/strong><\/p>\n

66. Musharrafieh R, Ma C, Wang J.* Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N\/L26I and M2-S31N\/V27A from the influenza A viruses. Eur. J. Pharm. Sci.<\/strong><\/em> 2019, 141, 105124. Link<\/a><\/p>\n

\"\"<\/p>\n

65. Ma C, Zhang J, Hu Y, Musharrafieh R, Wang J.* A novel capsid binding inhibitor displays potent antiviral activity against enterovirus D68. ACS Infect. Dis.<\/strong> <\/em>2019, 5, 1952-1962. Link<\/a><\/p>\n

\"\"<\/p>\n

64.\u00a0\u00a0Thomaston J, Wu Y, Polizzi N, Liu L, Wang J, DeGrado WF.* X-ray crystal structure of the influenza A M2 proton channel S31N mutant in two conformational states: an open and shut case. J. Am. Chem. Soc.<\/strong><\/em> 2019, 141, 11481-11488. Link<\/a><\/p>\n

\"\"<\/p>\n

63.\u00a0\u00a0Musharrafieh R, Lagarias P, Ma C, Tan G, Kolocouris A,* Wang J.* The L46P mutant confers a novel allosteric mechanism of resistance towards the influenza A virus M2 S31N proton channel blockers. Mol. Pharmacol.<\/strong><\/em> 2019, 96, 148-157. Link<\/a><\/p>\n

\"\"<\/p>\n

62.\u00a0\u00a0Zhang J, Hu Y, Hau R, Musharrafieh R, Ma C, Zhou X, Chen Y, Wang J.* Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses. \u200bEur. J. Pharm. Sci.<\/strong><\/em> 2019, 133, 86-94. Link<\/a><\/p>\n

\"\"<\/p>\n

61. Musharrafieh R, Zhang J, Tuohy P,\u00a0Kitamura N, Bellampalli SS, Hu Y, Khanna R, Wang J.* Discovery of quinoline analogous as potent antivirals against enterovirus D68 (EV-D68). J. Med. Chem.<\/strong> <\/em>2019, 62, 4074-4090. Link<\/a><\/p>\n

\"\"<\/p>\n

60. Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, Wang J.* Validating enterovirus D68 2Apro as an antiviral drug target and the discovery of telaprevir as a potent EV-D68-2Apro\u00a0inhibitor.\u00a0J. Virol.<\/strong><\/em> 2019, 93, e02221-18. (Spotlight feature article). Link<\/a><\/p>\n

\"\"<\/p>\n

Year 2018<\/span><\/strong><\/p>\n

59. Hu Y, Hau R, Wang Y, Tuohy P, Zhang Y, Xu S, Ma C, Wang J.* Structure-property relationship studies of influenza A virus AM2-S31N proton channel blockers. ACS. Med.\u00a0Chem. Lett.<\/strong><\/em> 2018, 9, 1111-1116. (highlighted by ScienceDaily, ACS PressPac, and EurekAlert). Link<\/a><\/p>\n

\"\"<\/p>\n

58.\u00a0Thomaston JL, Polizzi NF, Konstantinidi A, Wang J, Kolocouris A,* DeGrado WF.* (2018)\u00a0Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters.\u00a0J. Am. Chem. Soc.\u00a0<\/strong><\/em>140, 15219-15226. Link<\/a><\/p>\n

\"\"<\/p>\n

57. Zhang J, Hu Y, Musharrafieh R, Yin H, Wang J.* Focusing on the influenza polymerase complex: recent progress in drug discovery and assay development. Curr. Med. Chem.<\/strong> <\/em>2019, 26, 2243-2263. Link<\/a><\/p>\n

56.\u00a0Zhao X,\u00a0Li R,\u00a0Zhou Y,\u00a0Xiao M,\u00a0Ma C,\u00a0Yang Z,\u00a0Zeng S,\u00a0Du Q,\u00a0Yang C,\u00a0Jiang H,\u00a0Hu Y,\u00a0Wang K,\u00a0Mok CKP,\u00a0Sun P,\u00a0Dong J,\u00a0Cui W,\u00a0Wang J,\u00a0Tu Y,\u00a0Yang Z,\u00a0Hu W.* Discovery of highly potent pinanamine-based inhibitors against amantadine- and oseltamivir-resistant influenza A viruses.\u00a0 J. Med. Chem.<\/strong><\/em> 2018, 61, 5187-5198. Link<\/a><\/p>\n

\"\"<\/p>\n

55. Mandour YM,\u00a0Breitinger U,\u00a0Ma C,\u00a0Wang J,\u00a0Boeckler FM,\u00a0Breitinger HG,\u00a0Zlotos DP. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7. Drug Des. Devel. Ther.<\/strong><\/em> 2018, 12, 1019-1031. Link<\/a><\/p>\n

\"\"<\/p>\n

54. Zhang J, Hu Y, Foley C, Wang Y, Musharrafieh R, Xu ST,\u00a0Zhang YT, Ma C, Hulme C, Wang J.* Exploring Ugi-azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance. Sci. Rep.<\/strong> <\/em>2018, 8, 4653. Link<\/a><\/p>\n

\"\"<\/p>\n

53. Musharrafieh R, Ma C, Wang J.* Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Res.<\/strong><\/em> 2018, 153, 10-22. Link<\/a><\/p>\n

\"\"<\/p>\n

52. Drakopoulos A, Tzitzoglaki C, McGuire K, Hoffman A, Konstantinidi A, Kolokouris D, Ma C, Freudenberger K, Hutterer J, Gauglitz G, Wang J, Schmidtke M, Busath D, Kolocouris A.* Unraveling the binding, proton blockage, and inhibition of influenza M2 WT and S31N by rimantadine variants. ACS Med. Chem.\u00a0Lett.<\/strong><\/em> 2018, 9, 198-203. Link<\/a><\/p>\n

\"\"<\/p>\n

51. Wang Y, Hu Y, Xu S,\u00a0Zhang Y, Musharrafieh R, Hau R,\u00a0Ma C, \u00a0Wang J.* In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses.\u00a0 J. Med. Chem.<\/strong><\/em>\u00a0 2018, 61, 1074-1085. Link<\/a><\/p>\n

\"\"<\/p>\n

50. Ma C, Wang J.* Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses. Biochim. Biophys. Acta.-Biomembrane<\/strong><\/em> 2018, 1860, 272-280. Link<\/a><\/p>\n

\"\"<\/p>\n

Year 2017<\/strong><\/span><\/p>\n

49. Williams J, Shcherbakov A, Wang J, Hong M.* Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR. J. Biol. Chem.<\/strong><\/em> 2017, 292, 17876-17884. Link<\/a><\/p>\n

\"\"<\/p>\n

48. Hu Y, Zhang J, Musharrafieh R, Hau R,\u00a0Ma C, \u00a0Wang J.* Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral. Int. J. Mol. Sci.<\/strong><\/em> 2017, 18, E1929. Link<\/a><\/p>\n

\"\"<\/p>\n

47. Hu Y, Zhang J, Musharrafieh R, Ma C, Hau R, Wang J.* Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Res.<\/strong><\/em> 2017, 145, 103-113. Link<\/a><\/p>\n

\"\"\u200b46. Barniol-Xicota M, Gazzarrini S, Torres E, Hu Y, Wang J, Naesens L, Moroni A, Vazquez S.* Slow but steady wins the race: dissimilarities among new dual inhibitors of the wild-type and the V27A mutatn M2 channels of influenza A virus. J. Med. Chem.<\/strong><\/em> 2017, 60, 3727-3738. Link<\/a><\/p>\n

\"\"<\/p>\n

45. Hu Y, Wang Y, Fang L, Ma C, Wang J.* Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. Eur. J. Med. Chem.<\/strong><\/em> 2017, 135, 70-76. Link<\/a><\/p>\n

\"\"<\/p>\n

44. Hu Y, Sneyd H, Dekant R, Wang J.* Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr. Top. Med. Chem.<\/strong> <\/em>2017, 17, 2271-2285. Link<\/a><\/p>\n

43. \u00a0Li F, Hu Y, Wang Y, Ma C, Wang J.* Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki\u2013Miyaura Cross-Coupling Reaction.\u00a0 J. Med. Chem.<\/strong><\/em> 2017, 60, 1580-1590. Link<\/a><\/p>\n

\"\"<\/p>\n

42. Drakopoulos A, Tzitzoglaki C, Ma C, Freudenberger K, Hoffmann A, Hu Y, Gauglitz G, Schmidtke M, Wang J,* Kolocouris A,* Affinity of rimantadine enantiomers against Influenza A\/M2 protein Revisited. ACS Med. Chem. Lett.<\/strong><\/em> 2017, 8, 145-150. Link<\/a><\/p>\n

\"\"<\/p>\n

41. Hu Y, Musharrafieh R, Ma C, Zhang J, Smee D, DeGrado WF, Wang J.* An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Res.<\/strong><\/em> 2017, 140, 45-54 Link<\/a><\/p>\n

\"\"<\/p>\n

Year 2016<\/span><\/strong><\/p>\n

40. \u00a0Li F, Ma C, Hu Y, Wang Y, Wang J.* Discovery of potent antivirals against amantadine-resistant influenza A viruses by targeting the M2-S31N proton channel.\u00a0ACS Infect. Dis.<\/strong> <\/em>2016, 2, 726-133. Link<\/a><\/p>\n

\"\"<\/p>\n

39. Ma C, Li, F, Musharrafieh R, Wang J.* Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier to drug resistance. Antiviral Res.<\/strong><\/em> 2016, 133, 62-72. Link<\/a><\/p>\n

\"\"<\/p>\n

38. \u00a0Ma C, Zhang J, Wang J.* Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic barrier of Drug Resistance of M2-S31N Channel Blockers. Mol.\u00a0Pharmacol.<\/strong><\/em> 2016, mol.116.105346. Link<\/a><\/p>\n

\"\"<\/p>\n

37. \u00a0William J, Tietze D, Lee M, Wang J, Hong M.* Solid-State NMR Investigation of the Conformation, Proton Conductance, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel. J. Am. Chem. Soc.<\/strong> <\/em>2016, 138, 8143-8155. Link<\/a><\/p>\n

\"\"<\/p>\n

36. \u00a0Li F, Ma C, DeGrado WF, Wang J.* Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel. \u00a0J. Med. Chem.<\/strong><\/em> 2016, 59, 1207-1216. Link<\/a><\/p>\n

\"\"<\/p>\n

35. \u00a0Wang, J.* M2 as a target to combat influenza drug resistance: what does the evidence say? Future Virology<\/strong><\/em> (invited editorial) 2016, 11, 1-4. Link<\/a><\/p>\n

Year 2015<\/span><\/strong><\/p>\n

34. \u00a0Li F, Ma C, Wang J.* Inhibitors Targeting the Influenza Virus Hemagglutinin. Curr. Med. Chem.<\/strong> <\/em>2015, 22, 1361-1382. Link<\/a><\/p>\n

33. \u00a0Wang J,* Li F, Ma C. Recent Progress in Designing Inhibitors that Target the Drug-Resistant M2 Proton Channels from the Influenza A Viruses. Biopolymers: Peptide Science.<\/strong> <\/em>2015, 104, 291-309. Link<\/a><\/p>\n

Year 2014<\/span><\/strong><\/p>\n

32. \u00a0Wu Y, Canturk B, Jo H, Ma C, Gianti E, \u00a0Klein M, Pinto L, Lamb R, \u00a0Fiorin G,* Wang J,* DeGrado WF* Flipping in the pore: Discovery of Dual Inhibitors that Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. J. Am. Chem. Soc.<\/strong><\/em> 2014, 136, \u00a017987-13995. Link<\/a><\/p>\n

\"\"<\/p>\n

At the University of California, San Francisco (Postdoc work)<\/span><\/strong><\/p>\n

31. \u00a0Ghosh, A., Wang, J., Moroz, Y. S., Korendovych, I. V., Zanni, M. T., DeGrado, W. F., and Hochstrasser, R. M. 2D IR Spectroscopy Reveals the Role of Water in the Binding of Channel-Blocking Drugs to the Influenza M2 Channel. \u00a0J. Chem. Phys.<\/strong><\/em> 2014, 40, 235105.<\/p>\n

30. \u00a0Montalvo, G. L., Zhang, Y., Young, T. M., Costanzo, M. J., Freeman, K. B., Wang, J., Clements, D. J., Magavern, E., Kavash, R. W., Scott, R. W., Liu, D., and DeGrado, W. F.\u00a0 De Novo Design of Self-Assembling Foldamers That Inhibit Heparin-Protein Interactions. ACS Chem. Biol.<\/strong> <\/em>2014, 9, 967-975.<\/p>\n

29. \u00a0Rey-Carrizo, M., Torres, E., Ma, C., Barniol-Xicota, M., Wang, J., Wu, Y., Naesens, L., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. M2 ion channel of influenza A virus: from wild-type inhibitors to compounds with potent activity against the V27A mutant.\u00a0 J. Med. Chem.<\/strong><\/em> 2013, 56, 9265-9274.<\/p>\n

28. \u00a0Ma, C. L., Fiorin, G., Carnevale, V., Wang, J., Lamb, R. A., Klein, M. L., Wu, Y. B., Pinto, L. H., and DeGrado, W. F. Asp44 stabilizes the Trp41 gate of the M2 proton channel of influenza A virus. Structure<\/strong><\/em> 2013, 21, 2033-2041.<\/p>\n

27. \u00a0Wang, J., Wu, Y., Ma, C., Fiorin, G., Wang, J., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.\u00a0 Proc. Natl. Acad. Sci. U. S. A.<\/strong><\/em>\u00a02013, 110, 1315-1320. Highlighted by Science-Business eXchange (SciBX).<\/p>\n

26. \u00a0Williams, J. K., Tietze, D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.\u00a0 J. Am. Chem. Soc.<\/strong><\/em> 2013, 135, 9885-9897. Highlighted by JACS.<\/p>\n

25.\u00a0\u00a0Wang, J., Ma, C., Wang, J., Jo, H., Canturk, B., Fiorin, G., Pinto, L. H., Lamb, R. A., Klein, M. L., and DeGrado, W. F. Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. \u00a0J. Med. Chem.<\/strong><\/em> 2013, 56, 2804-2812.<\/p>\n

24.\u00a0\u00a0Thomaston, J. L., Nguyen, P. A., Brown, E. C., Upshur, M. A., Wang, J., DeGrado, W. F., and Howard, K. P. Detection of drug-induced conformational change of a transmembrane protein in lipid bilayers using site-directed spin labeling. Protein Sci.<\/strong><\/em> 2013, 22, 65-73.<\/p>\n

23.\u00a0\u00a0Schmidt, N. W., Mishra, A.,# Wang, J.,# DeGrado, W. F., and Wong, G. C. Influenza virus a m2 protein generates negative gaussian membrane curvature necessary for budding and scission. J. Am. Chem. Soc.<\/strong><\/em> 2013, 135, 13710-13719.<\/p>\n

22.\u00a0\u00a0Mao, L., Wang, J., DeGrado, W. F., and Inouye, M. An assay suitable for high throughput screening of anti-influenza drugs. Plos One<\/strong><\/em> 2013, 8, e54070<\/p>\n

21.\u00a0\u00a0Balgi, A. D.,# Wang, J.,# Cheng, D. Y., Ma, C., Pfeifer, T. A., Shimizu, Y., Anderson, H. J., Pinto, L. H., Lamb, R. A., DeGrado, W. F., and Roberge, M. Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay. Plos One<\/strong><\/em> 2013, 8, e55271.<\/p>\n

At the University of Pennsylvania (PhD work)<\/strong><\/span><\/p>\n

20.\u00a0\u00a0Wang, J., Qiu, J. X., Soto, C., and DeGrado, W. F. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. \u00a0Curr. Opin. Struct. Biol.<\/strong><\/em> 2011, 21, 68-80.<\/p>\n

19.\u00a0\u00a0Wang, J., Ma, C., Wu, Y., Lamb, R. A., Pinto, L. H., and DeGrado, W. F. Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. J. Am. Chem. Soc.<\/strong><\/em> 2011, 133, 13844-13847. Highlighted by Faculty 1000.<\/p>\n

18.\u00a0\u00a0Wang, J., Ma, C., Fiorin, G., Carnevale, V., Wang, T., Hu, F., Lamb, R. A., Pinto, L. H., Hong, M., Klein, M. L., and DeGrado, W. F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. \u00a0J. Am. Chem. Soc.<\/strong><\/em> 2011, 133, 12834-12841. Highligted by Faculty 1000.<\/p>\n

17.\u00a0\u00a0Wang, J., Ma, C., Balannik, V., Pinto, L. H., Lamb, R. A., and DeGrado, W. F. Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in inhibitors of M2 from Influenza A Virus. \u00a0ACS Med. Chem. Lett.<\/strong> <\/em>2011, 2, 307-312.<\/p>\n

16.\u00a0\u00a0Rogers, J. M., Polishchuk, A. L., Guo, L., Wang, J., DeGrado, W. F., and Gai, F. Photoinduced electron transfer and fluorophore motion as a probe of the conformational dynamics of membrane proteins: application to the influenza a M2 proton channel. \u00a0Langmuir<\/strong><\/em> 2011, 27, 3815-3821.<\/p>\n

15.\u00a0\u00a0Duque, M. D., Ma, C., Torres, E., Wang, J., Naesens, L., Juarez-Jimenez, J., Camps, P., Luque, F. J., DeGrado, W. F., Lamb, R. A., Pinto, L. H., and Vazquez, S. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. \u00a0J. Med. Chem.<\/strong><\/em> 2011, 54, 2646-2657.<\/p>\n

14.\u00a0\u00a0Cady, S. D., Wang, J., Wu, Y., DeGrado, W. F., and Hong, M. Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. \u00a0J. Am. Chem. Soc.<\/strong><\/em> 2011, 133, 4274-4284.<\/p>\n

13.\u00a0\u00a0Leiding, T., Wang, J., Martinsson, J., DeGrado, W. F., and Arskold, S. P. Proton and cation transport activity of the M2 proton channel from influenza A virus. Proc. Natl. Acad. Sci. U. S. A.<\/strong> <\/em>2010, 107, 15409-15414.<\/p>\n

12.\u00a0\u00a0Cady, S. D., Schmidt-Rohr, K., Wang, J., Soto, C. S., DeGrado, W. F., and Hong, M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature<\/strong><\/em> 2010, 463, 689-692.<\/p>\n

11.\u00a0\u00a0Balannik, V., Obrdlik, P., Inayat, S., Steensen, C., Wang, J., Rausch, J. M., DeGrado, W. F., Kelety, B., and Pinto, L. H. Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. Pflugers Archiv : European journal of physiology<\/strong><\/em> 2010, 459, 593-605.<\/p>\n

10.\u00a0\u00a0Wang, J., Cady, S. D., Balannik, V., Pinto, L. H., DeGrado, W. F., and Hong, M. Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. \u00a0J. Am. Chem. Soc.<\/strong><\/em> 2009, 131, 8066-8076. Highlighted by ACS Chemical Biology.<\/p>\n

9.\u00a0\u00a0Balannik, V.,# Wang, J.,# Ohigashi, Y., Jing, X., Magavern, E., Lamb, R. A., DeGrado, W. F., and Pinto, L. H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.\u00a0Biochemistry<\/strong><\/em> 2009, 48, 11872-11882.<\/p>\n

At the National University of Singapore (Master work)<\/span><\/strong><\/p>\n

8.\u00a0\u00a0Uttamchandani, M., Wang, J., Li, J., Hu, M., Sun, H., Chen, K. Y., Liu, K., and Yao, S. Q. Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. J. Am. Chem. Soc.<\/strong><\/em> 2007, 129, 7848-7858.<\/p>\n

7.\u00a0\u00a0Uttamchandani, M., Lee, W. L., Wang, J., and Yao, S. Q. Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays. \u00a0J. Am. Chem. Soc.<\/strong> <\/em>2007, 129, 13110-13117.<\/p>\n

6.\u00a0\u00a0Wang, J., Uttamehandani, M., Sun, H. Y., and Yao, S. Q. Small molecule microarrays: Applications using specially tagged chemical libraries. QSAR Comb. Sci.<\/strong> <\/em>2006, 25, 1009-1019.<\/p>\n

5.\u00a0\u00a0Wang, J., Uttamchandani, M., Sun, L. P., and Yao, S. Q. Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays. Chem. Commun.<\/strong><\/em> 2006, 717-719.<\/p>\n

4.\u00a0\u00a0Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. Rapid assembly of matrix metalloprotease inhibitors using click chemistry. Org. Lett.<\/strong><\/em> 2006, 8, 3821-3824.<\/p>\n

3.\u00a0\u00a0Wang, J., Uttamchandani, M., Li, J., Hu, M., and Yao, S. Q. “Click” synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases. Chem. Commun.<\/strong><\/em>\u00a02006, 3783-3785. Highlighted as ‘hot paper’ by Chem. Commun., Chemical Society Magazine and Chemistry World.<\/p>\n

2.\u00a0 Uttamchandani, M., Wang, J., and Yao, S. Q. Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Mol. Biosyst.<\/strong><\/em> 2006, 2, 58-68.<\/p>\n

1.\u00a0\u00a0Sun, H., Chattopadhaya, S., Wang, J., and Yao, S. Q. Recent developments in microarray-based enzyme assays: from functional annotation to substrate\/inhibitor fingerprinting. Anal. Bioanal. Chem.<\/strong><\/em> 2006, 386, 416-426.<\/p>\n

<\/h3>\n

Patents<\/strong><\/h3>\n

Wang, J.\u00a0<\/strong>Therapeutic compounds and methods. US20250051283A1. (EV-D68 2Apro inhibitors).<\/p>\n

Wang, J.\u00a0<\/strong>Therapeutic compounds. US20240382494A1. (SARS-CoV-2 quinoline PLpro inhibitors).<\/p>\n

Wang, J.,<\/strong> Hu, Y., Li, K. Therapeutic compounds. WO2024206284A2. (EV-D68 VP1 inhibitors).<\/p>\n

Wang, J.,<\/strong> Tan, B., Jadhav, P., Ansari A., Chopra A., Figueras F., Arnold, E. Therapeutic compounds. WO2024178004A3. (SARS-CoV-2 PLpro inhibitors).<\/p>\n

Wang, J. <\/strong>Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection. US11866407B2.<\/p>\n

Wang, J., <\/strong>Kitamura, N. Compositions and methods for inhibiting viral protein 2C activity for preventing and treating non-polio enterovirus infection. US11834451B2.<\/p>\n

Wang, J., <\/strong>Hu, Y., Ma, C.L., Kitamura, N. Compositions and methods for inhibiting PLpro protease activity and for preventing and treating SARS-CoV-2 infection. US20240325321A1<\/span>, WO2022192665A1.<\/p>\n

Wang, J., <\/strong>Kitamura, N., Ma, C.L. Compositions and methods for inhibiting Mpro protease activity and for preventing and treating SARS-CoV-2 infection. US20240083885A1<\/span>, WO2022119756A9.<\/p>\n

Wang, J., <\/strong>Ma, C.L. Small molecule inhibitors of SARS-CoV-2 viral replication and uses thereof. US20230148179A1<\/span>,<\/span> WO2021207409A3.<\/p>\n

Wang, J., <\/strong>Rajesh Khanna. Small molecule inhibitors of Cav3.2 activity and uses thereof. US20230365544A1<\/span><\/p>\n

Wang, J., <\/strong>Rajesh Khanna. Small molecule inhibitors of Cav3.2 activity and uses thereof. US20230192674A1<\/span>, WO2021231553A1.<\/p>\n

Wang, J.,<\/strong> Musharrafieh, R., Ma, C.L., Zhang, J.T., Hu, Y.M. Small molecule enterovirus inhibitors and uses thereof.\u00a0 US20210244721A1.<\/p>\n

Wang, J.,<\/strong> Ma, C.L., Hulme, C. Methods and compositions for the treatment of influenza.\u00a0 US2019089734A1, WO2019089734A1<\/span><\/p>\n

DeGrado, W. F., Wang, J, Wang, J<\/strong>., Jo, H., Canturk, B. Inhibitors targeting drug-resistant influenza A. US9884832B2, WO2013086131A1.<\/p>\n

DeGrado, W. F., Wang, J<\/strong>. Influenza A virus inhibition. US9464075B2, WO2010033339A1<\/span><\/p>\n

DeGrado, W. F., Wang, J<\/strong>. Inhibition of influenza A virus M2 proton channel. US9453005B2.<\/p>\n

DeGrado, W. F., Wang, J<\/strong>. Adamantane analogs. US9301950B2.<\/p>\n

DeGrado, W. F., Wang, J<\/strong>. Inhibitors of the influenza A virus M2 proton channel. US9403777B2<\/span>.<\/p>\n

DeGrado, W. F., Wang, J<\/strong>. Spiro-piperidine inhibitors. US8557836B2.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

For complete list of publications: Google Scholar ORCID Publons PubMed Publications (# equal contribution * Corresponding author) Year 2026 138. Li K, Ni J, Fan G, Wang J* Rational design … Read More<\/a><\/p>\n","protected":false},"author":21,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-custom.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-363","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nPublications - Jun Wang Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - Jun Wang Lab\" \/>\n<meta property=\"og:description\" content=\"For complete list of publications: Google Scholar ORCID Publons PubMed Publications (# equal contribution * Corresponding author) Year 2026 138. Li K, Ni J, Fan G, Wang J* Rational design … Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"Jun Wang Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T19:32:16+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015-300x151.jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"46 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/\",\"url\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/\",\"name\":\"Publications - Jun Wang Lab\",\"isPartOf\":{\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015-300x151.jpeg\",\"datePublished\":\"2020-07-09T16:51:59+00:00\",\"dateModified\":\"2026-03-23T19:32:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage\",\"url\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015.jpeg\",\"contentUrl\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015.jpeg\",\"width\":1000,\"height\":503},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/#website\",\"url\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/\",\"name\":\"Jun Wang Lab\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sites.rutgers.edu\/jun-wang-lab\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - Jun Wang Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/","og_locale":"en_US","og_type":"article","og_title":"Publications - Jun Wang Lab","og_description":"For complete list of publications: Google Scholar ORCID Publons PubMed Publications (# equal contribution * Corresponding author) Year 2026 138. Li K, Ni J, Fan G, Wang J* Rational design … Read More","og_url":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/","og_site_name":"Jun Wang Lab","article_modified_time":"2026-03-23T19:32:16+00:00","og_image":[{"url":"http:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015-300x151.jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"46 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/","url":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/","name":"Publications - Jun Wang Lab","isPartOf":{"@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage"},"image":{"@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage"},"thumbnailUrl":"http:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015-300x151.jpeg","datePublished":"2020-07-09T16:51:59+00:00","dateModified":"2026-03-23T19:32:16+00:00","breadcrumb":{"@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#primaryimage","url":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015.jpeg","contentUrl":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-content\/uploads\/sites\/745\/2026\/03\/images_large_au6c00039_0015.jpeg","width":1000,"height":503},{"@type":"BreadcrumbList","@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/#website","url":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/","name":"Jun Wang Lab","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/pages\/363"}],"collection":[{"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/comments?post=363"}],"version-history":[{"count":106,"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/pages\/363\/revisions"}],"predecessor-version":[{"id":840,"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/pages\/363\/revisions\/840"}],"wp:attachment":[{"href":"https:\/\/sites.rutgers.edu\/jun-wang-lab\/wp-json\/wp\/v2\/media?parent=363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}